Imricor Medical Systems is advancing the electrophysiology field by allowing physicians to perform cardiac ablation procedures in the growing number of interventional magnetic resonance (iCMR) suites found or being developed in leading hospitals.

In this episode, we are joined by Imricor’s Global Sales Leader, Greg Englehardt, to share the journey and their mission of bringing not just a set of innovative surgical tools to market, but also an entirely new operating environment! Where other larges companies have tried and failed, Greg details how the company has navigated an array of technical challenges to make their solution successful.

Between gaining Imricor’s CE mark approval and navigating a product launch during the pandemic, combined with Greg’s extensive experience with startups, this discussion is packed with insights. If you want to learn more about their upcoming US market development and how you could be part of a growing team then be sure to tune in so you can be informed and inspired.

Deep brain stimulation (DBS) is a neurosurgical procedure that treats neurological conditions by implanting electrodes into the brain to produce electrical impulses. These impulses can control abnormal brain activity and chemical imbalances that cause conditions like Parkinson's disease, essential tremor, and dystonia.

Despite the benefits of DBS, less than 1% of the 25 million patients who are eligible to undergo the procedure opt-in due to the invasiveness of and risk associated with traditional open brain surgery. Nicky Driscoll, CTO of NeuroBionics, joins this episode to share how their team is on a mission to change the status quo through bioelectronic medicine. NeuroBionics is developing devices that seamlessly integrate with the human body and aim to offer DBS with a minimally-invasive approach.

As well as learning about this exciting technology, Nicky shares insights into the journey from academic researcher to entrepreneur, and how they decided to focus on a challenging commercialization journey that could positively impact patient lives. As one of the top startups in the M2D2 accelerator program and recent winners of the 2024 Vision Award with Medtech Innovator, the NeuroBionics story is definitely one to follow, and is sure to leave you informed and inspired.

Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on safely and effectively treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital and Cue Growth Partners to develop their innovative Pulse IVL System that has recently received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial.

Angie Volk, VP of Business Development, and Sean Gilligan, COO of AVS, join this episode to share about their team’s mission and how they are bringing this exciting technology to market. With Johnson & Johnson’s $13.3B acquisition earlier this year of Shockwave Medical, the IVL space is showing that it is currently one of the hottest spaces in medtech. We discuss how AVS’s Pulse IVL System is being designed to easily deliver therapy across complex calcified lesions and reduce overall procedural costs, making it hugely attractive to potential future acquirers.

As former Boston Scientific colleagues, Angie and Sean have extensive industry experience including unique insights of building a winning culture, and they are leveraging these learnings and their network to efficiently navigate their solution to patients across the globe. With two medtech veterans, this is a conversation brimming with helpful tips for any would-be entrepreneur that is sure to leave you informed and inspired.

The Future Health Index (FHI) survey conducted by Philips, a global leader in health technology, explores the challenges within healthcare systems and the innovative solutions being used to address them. From the survey findings, the recently released ninth annual report - 'Better Care for More People', demonstrates the pressures of staffing shortages and burnout on clinicians, and their ability to deliver timely, high-quality care to patients.

Jeff DiLullo, Chief Region Leader for Philips North America, joins this episode to discuss the findings and share how Philips is utilizing collaborative innovation to address the challenges. Jeff highlights the investments that healthcare leaders are making to help ease the burden on staff, such as automation and artificial intelligence, and those that are having an impact on increasing access and health equity such as virtual care.

Technology adoption is no longer a choice, but an imperative that leaders like Jeff are working with the community to bring solutions to where they are needed most. From AI to telehealth and virtual care, this conversation is a calling card to those who want to work together to foster innovation. Listen in for some wonderful takeaways from Jeff, and be sure to check out the Future Health Index 2024 Report so you can be informed and inspired.

Founded in 2017, XCath is a dynamic startup at the cutting edge of revolutionary medical robotics, nanorobotics and materials science. The company develops next-generation endovascular robotic systems and steerable guidewires to treat life-threatening conditions like cerebrovascular disorders.

With strategically located campuses in Houston, Texas – home to the world's largest medical center – and Pangyo, South Korea, often referred to as the Silicon Valley of Korea, XCath is committed to bringing its innovative solutions to patients around the world. CEO Eduardo Fonseca joins this episode to share how their family of engineers is making this a reality, with a value driven culture, and space-edge approach.

After recently performing the world’s first public telerobotic mechanical thrombectomy at Abu Dhabi Global Healthcare Week, it’s clear that the XCath team is helping pave the way for widescale implementation of robotic surgical tools. Eduardo outlines how the team is building on this momentous landmark to tackle the eye-watering statistics associated with stroke, a conversation that is sure to leave you informed and inspired.

Strokes are caused by blocked blood flow to the brain (ischemic stroke) or sudden bleeding in the brain (hemorrhagic stroke). About 87% of strokes are ischemic with the blockage in the brain usually caused by a piece of plaque or a blood clot.

Like fingerprints, no two strokes are the same. Yet, conventional therapy options are limited and can compromise patient safety.​​ Rapid Medical’s CEO and co-founder, Ronen Eckhouse joins this episode to share how they are bringing critical innovation to tackle ischemic strokes and enable physicians to respond in real-time to the brain’s complex anatomy, helping tailor the procedure to every patient.

Rapid Medical’s uniquely designed stent is hard on the clot but soft on the vessel, this allows physicians to actively adapt to the fragile environment found in the brain. Ronen shares how the company has built value through strong partnerships, a growing patent portfolio, and ultimately helped bring enhanced outcomes for stroke patients in countries across the globe. With a long-term mission to solve big problems and some exciting new innovation on the horizon, Ronen’s journey is one sure to leave you informed and inspired.

Vasectomy is a form of male birth control that cuts the supply of sperm to semen by cutting and sealing the tubes that carry sperm. The procedure has a low risk of problems and can usually be performed in an outpatient setting under local anesthesia. Despite contraceptive use worldwide increasing by 188 million users in the past 20 years, the number of vasectomy users fell by 27 million, a 61% decline, with almost all low-and-middle income countries reporting negligible vasectomy use. Female-to-male disparities in permanent method use have also widened further in the same period.

Joining this episode, Signati Medical’s CEO and Founder William ‘Billy’ Prentice, shares how their company is dedicated to advancing men’s health and changing the status quo. Signati plans to launch the first innovation in vasectomy in more than 20 years with a procedure that would be fast for physicians and comfortable for patients. Designed to take just minutes, this could be done right in the urologist’s office and would offer easier recovery compared to some current techniques.



From the get-go, Billy’s drive and motivation to advance the accessibility of this procedure and reduce the burden of responsibility on women, is evident. From Wall Street trader turned entrepreneur, the story of Signati and Billy’s journey is stacked with insights that are sure to leave you informed and inspired.

Hair loss affects more than 80 million Americans—approximately 50 million men and 30 million women. This market is large and complex, but most importantly, it represents a wide range of patients. For about 25% of American men, the balding process begins in their 20s and almost 85% will experience noticeable hair loss by their 50s. Women, on the other hand, can lose their hair for a variety of reasons ranging from postpartum hormones to menopause.

Traditional transplant remedies can be invasive, leaving a linear scar, and incur significant downtime. In contrast, Venus hair restoration equipment provides the right tools for the physician to create a natural-looking hairline for their patients. Joseph ‘Joey’ Brown, Global VP of Venus hair joins this episode to share how they are blending artificial intelligence with robotics to bring a new standard of treatment for patients.

As someone who has suffered from hair loss himself, Joey shares honest insights into the mental anxiety faced, and why despite recent advance in hair transplant techniques, the robotic technology available via Venus’s ARTAS system, offers a new elevated level of accuracy and precision not previously seen before in the procedure. With more than 25 years of extensive industry knowledge, combined with Joey’s passion for helping other patients tackle their hair loss condition, this conversation is sure to leave you informed and inspired.